Xbrane Biopharma Past Earnings Performance
Past criteria checks 0/6
Xbrane Biopharma's earnings have been declining at an average annual rate of -17.7%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 77.1% per year.
Key information
-17.7%
Earnings growth rate
5.2%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 77.1% |
| Return on equity | -188.0% |
| Net Margin | -134.9% |
| Next Earnings Update | 16 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Xbrane Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 239 | -322 | 40 | 306 |
| 30 Sep 23 | 189 | -285 | 43 | 286 |
| 30 Jun 23 | 144 | -246 | 41 | 256 |
| 31 Mar 23 | 112 | -189 | 36 | 222 |
| 31 Dec 22 | 58 | -169 | 32 | 200 |
| 30 Sep 22 | 43 | -146 | 27 | 169 |
| 30 Jun 22 | 32 | -147 | 29 | 154 |
| 31 Mar 22 | 15 | -172 | 31 | 151 |
| 31 Dec 21 | 11 | -183 | 31 | 161 |
| 30 Sep 21 | 8 | -213 | 32 | 189 |
| 30 Jun 21 | 5 | -219 | 26 | 200 |
| 31 Mar 21 | 3 | -215 | 27 | 195 |
| 31 Dec 20 | 0 | -218 | 27 | 197 |
| 30 Sep 20 | 0 | -222 | 29 | 176 |
| 30 Jun 20 | 0 | -210 | 32 | 160 |
| 31 Mar 20 | 0 | -204 | 30 | 156 |
| 31 Dec 19 | 0 | -188 | 27 | 138 |
| 30 Sep 19 | 5 | -154 | 25 | 127 |
| 30 Jun 19 | 7 | -56 | 27 | 108 |
| 31 Mar 19 | 12 | -40 | 24 | 95 |
| 31 Dec 18 | 20 | -13 | 24 | 86 |
| 30 Sep 18 | 25 | 0 | 22 | 78 |
| 30 Jun 18 | 23 | -69 | 15 | 72 |
| 31 Mar 18 | 23 | -45 | 14 | 50 |
| 31 Dec 17 | 21 | -45 | 13 | 38 |
| 30 Sep 17 | 11 | -35 | 10 | 30 |
| 30 Jun 17 | 11 | -34 | 10 | 31 |
| 31 Mar 17 | 6 | -31 | 6 | 32 |
| 31 Dec 16 | 0 | -28 | 8 | 24 |
| 30 Sep 16 | 0 | -24 | 11 | 14 |
| 30 Jun 16 | 0 | -19 | 13 | 7 |
| 31 Mar 16 | 1 | -16 | 14 | 0 |
| 31 Dec 15 | 0 | -12 | 11 | 0 |
| 30 Sep 15 | 2 | -8 | 10 | 0 |
| 31 Dec 14 | 2 | -3 | 4 | 0 |
| 31 Dec 13 | 0 | -2 | 2 | 0 |
Quality Earnings: XBRANS is currently unprofitable.
Growing Profit Margin: XBRANS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XBRANS is unprofitable, and losses have increased over the past 5 years at a rate of 17.7% per year.
Accelerating Growth: Unable to compare XBRANS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XBRANS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.8%).
Return on Equity
High ROE: XBRANS has a negative Return on Equity (-187.95%), as it is currently unprofitable.